DE60132567D1 - Carbamat caspase inhibitoren und deren verwendung - Google Patents

Carbamat caspase inhibitoren und deren verwendung

Info

Publication number
DE60132567D1
DE60132567D1 DE60132567T DE60132567T DE60132567D1 DE 60132567 D1 DE60132567 D1 DE 60132567D1 DE 60132567 T DE60132567 T DE 60132567T DE 60132567 T DE60132567 T DE 60132567T DE 60132567 D1 DE60132567 D1 DE 60132567D1
Authority
DE
Germany
Prior art keywords
caspase inhibitors
carbamate
carbamate caspase
inhibitors
caspase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60132567T
Other languages
English (en)
Other versions
DE60132567T2 (de
Inventor
David Bebbington
Jean-Damien Charrier
David Kay
Ronald Knegtel
Julian Golec
Michael Mortimore
John Studley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60132567D1 publication Critical patent/DE60132567D1/de
Publication of DE60132567T2 publication Critical patent/DE60132567T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/30—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with acyl radicals attached to the ring nitrogen atom
DE60132567T 2000-03-29 2001-03-29 Carbamat caspase inhibitoren und deren verwendung Expired - Lifetime DE60132567T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19282600P 2000-03-29 2000-03-29
US192826P 2000-03-29
PCT/US2001/010182 WO2001072707A2 (en) 2000-03-29 2001-03-29 Carbamate caspase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
DE60132567D1 true DE60132567D1 (de) 2008-03-13
DE60132567T2 DE60132567T2 (de) 2009-01-22

Family

ID=22711181

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132567T Expired - Lifetime DE60132567T2 (de) 2000-03-29 2001-03-29 Carbamat caspase inhibitoren und deren verwendung

Country Status (32)

Country Link
US (2) US6689784B2 (de)
EP (1) EP1268425B1 (de)
JP (2) JP4298200B2 (de)
KR (1) KR100858640B1 (de)
CN (2) CN1994298A (de)
AR (1) AR027993A1 (de)
AT (1) ATE384695T1 (de)
AU (2) AU2001249619B2 (de)
BG (1) BG107136A (de)
BR (1) BR0109588A (de)
CA (1) CA2403959A1 (de)
CZ (1) CZ20023227A3 (de)
DE (1) DE60132567T2 (de)
DK (1) DK1268425T3 (de)
EA (1) EA005740B1 (de)
EE (1) EE200200550A (de)
ES (1) ES2296742T3 (de)
HK (1) HK1052355B (de)
HR (1) HRP20020782A2 (de)
HU (1) HUP0301472A3 (de)
IL (2) IL151829A0 (de)
MX (1) MXPA02009633A (de)
NO (1) NO325062B1 (de)
NZ (1) NZ521639A (de)
PE (1) PE20011267A1 (de)
PL (1) PL201081B1 (de)
PT (1) PT1268425E (de)
SK (1) SK13922002A3 (de)
TW (1) TWI318207B (de)
WO (1) WO2001072707A2 (de)
YU (1) YU73702A (de)
ZA (1) ZA200207483B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01010127A (es) 1999-04-09 2002-08-20 Cytovia Inc Inhibidores de la caspasa y el uso de los mismos.
BR0013666A (pt) 1999-08-27 2002-05-14 Cytovia Inc "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso
CN1994298A (zh) * 2000-03-29 2007-07-11 沃泰克斯药物股份有限公司 氨基甲酸酯天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US20040192889A1 (en) * 2001-03-30 2004-09-30 Dale Bredesen Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
US7351702B2 (en) * 2001-05-23 2008-04-01 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
EP1485107A1 (de) 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipide als caspase-hemmer-prodrugs
EP1499898A2 (de) * 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulierung von tnf-alpha
EP1447093A1 (de) * 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition des CD95 Ligand/Rezeptorsystems zur Behandlung neurologischer Störungen und Verletzungen
US20060217299A1 (en) * 2003-02-24 2006-09-28 Hirofumi Doi Degradation inhibitor for hepatitis b virus x interacting protein
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
KR101135765B1 (ko) 2004-03-12 2012-04-23 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
JP4848367B2 (ja) * 2004-05-15 2011-12-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｃｅインヒビターを使用した発作の処置
KR100619440B1 (ko) 2004-05-20 2006-09-08 한기종 포름아마이드 유도체 제조방법
EP2295054A1 (de) 2004-05-27 2011-03-16 Vertex Pharmaceuticals Incorporated Ice-hemmer zur Behandlung von autoinflammatorischen Erkrankungen
KR100619439B1 (ko) 2004-05-27 2006-09-08 한기종 포밀기 도입된 아민유도체의 제조방법
US8012751B2 (en) * 2005-03-31 2011-09-06 Wisconsin Alumni Research Foundation Differentiation of pluripotent embryonic stem cells
CA2616337A1 (en) * 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
US8073703B2 (en) 2005-10-07 2011-12-06 Panasonic Corporation Acoustic signal processing apparatus and acoustic signal processing method
EP1956898A2 (de) 2005-11-30 2008-08-20 Massachusetts Institute of Technology Zellbewahrungssysteme mit funktion zur erkennung von krankheitserregern
CA2649877A1 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
CA2656487A1 (en) * 2006-07-07 2008-01-17 The Board Of Trustees Of The Leland Stanford Junior University Selective caspase inhibitors
WO2008021745A2 (en) * 2006-08-16 2008-02-21 Itherx Pharmaceuticals, Inc. Hepatitis c virus entry inhibitors
WO2008063727A2 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
WO2008137567A1 (en) * 2007-05-01 2008-11-13 Cedars-Sinai Medical Center Caspase inhibitors in the treatment of infection-associated preterm delivery
KR101009588B1 (ko) * 2008-06-04 2011-01-20 거진산업주식회사 미세여과막을 이용한 부유고형물 처리장치
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
KR101010350B1 (ko) * 2009-03-26 2011-01-25 삼성중공업 주식회사 역세척 여과장치
US20140309172A1 (en) 2010-11-05 2014-10-16 Dagmar Ringe Ice inhibiting compounds and uses thereof
TW201236239A (en) * 2010-11-16 2012-09-01 Solvay Rechargeable metal or metal-ion cell
EP2490021A1 (de) 2011-02-18 2012-08-22 Biotempt B.V. Modulatoren von PRR- und GPCR-Signalisierung
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
WO2015175381A1 (en) 2014-05-12 2015-11-19 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko) 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
CA3039283A1 (en) 2016-10-05 2018-04-12 Novartis Ag Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder
CN110944985B (zh) * 2017-05-24 2022-12-13 特拉维夫大学拉玛特有限公司 用于蛋白酶的成像/检测的化学发光探针
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015577A1 (en) 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
HU220098B (hu) 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok
EP0618223A3 (de) 1993-03-08 1996-06-12 Sandoz Ltd Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe.
WO1996030395A2 (en) 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
WO1997024339A1 (fr) 1995-12-27 1997-07-10 Ono Pharmaceutical Co., Ltd. Derives de tetrazole et medicaments les contenant a titre d'ingredients actifs
JP3492703B2 (ja) 1996-09-12 2004-02-03 アイドゥン ファーマシューティカルズ，インコーポレイテッド システインプロテアーゼのＩＣＥ／ｃｅｄ―３ファミリーの阻害剤としてのＣ―末端変性（Ｎ―置換）―２―インドリルジペプチド
BR9712987A (pt) * 1996-10-11 2000-04-18 Warner Lambert Co Inibidores de enzima de conversão de interleucina-1beta de sulfonamida
WO1998016502A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
CN1138472C (zh) 1997-10-10 2004-02-18 西托维亚公司 二肽型编程性细胞死亡抑制剂及其用途
JP2002506829A (ja) 1998-03-16 2002-03-05 サイトビア インコーポレイテッド ジペプチドのアポトーシスインヒビターおよびそれらの使用
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
DE60030097T2 (de) 1999-03-16 2007-03-08 Cytovia, Inc., San Diego Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
MXPA01010127A (es) 1999-04-09 2002-08-20 Cytovia Inc Inhibidores de la caspasa y el uso de los mismos.
BR0013666A (pt) * 1999-08-27 2002-05-14 Cytovia Inc "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso
CN1994298A (zh) * 2000-03-29 2007-07-11 沃泰克斯药物股份有限公司 氨基甲酸酯天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途

Also Published As

Publication number Publication date
PT1268425E (pt) 2008-04-01
JP2008266348A (ja) 2008-11-06
SK13922002A3 (sk) 2003-09-11
DE60132567T2 (de) 2009-01-22
PL358430A1 (en) 2004-08-09
WO2001072707A3 (en) 2002-05-23
AU4961901A (en) 2001-10-08
WO2001072707A2 (en) 2001-10-04
US20040053920A1 (en) 2004-03-18
KR20020086711A (ko) 2002-11-18
EA200201030A1 (ru) 2003-02-27
PL201081B1 (pl) 2009-03-31
HRP20020782A2 (en) 2004-12-31
CA2403959A1 (en) 2001-10-04
NO325062B1 (no) 2008-01-28
EA005740B1 (ru) 2005-06-30
MXPA02009633A (es) 2003-03-10
ATE384695T1 (de) 2008-02-15
CZ20023227A3 (cs) 2003-01-15
HK1052355A1 (en) 2003-09-11
PE20011267A1 (es) 2001-12-15
NZ521639A (en) 2004-05-28
IL151829A0 (en) 2003-04-10
JP2003528855A (ja) 2003-09-30
BR0109588A (pt) 2003-02-04
ZA200207483B (en) 2003-09-18
AR027993A1 (es) 2003-04-23
KR100858640B1 (ko) 2008-09-17
EP1268425B1 (de) 2008-01-23
CN1422253A (zh) 2003-06-04
NO20024661D0 (no) 2002-09-27
TWI318207B (en) 2009-12-11
BG107136A (bg) 2003-05-30
US6689784B2 (en) 2004-02-10
HUP0301472A2 (hu) 2003-08-28
DK1268425T3 (da) 2008-05-05
HUP0301472A3 (en) 2005-04-28
YU73702A (sh) 2006-03-03
CN1994298A (zh) 2007-07-11
NO20024661L (no) 2002-11-26
EP1268425A2 (de) 2003-01-02
ES2296742T3 (es) 2008-05-01
CN100358869C (zh) 2008-01-02
AU2001249619B2 (en) 2006-08-17
JP4298200B2 (ja) 2009-07-15
EE200200550A (et) 2004-02-16
HK1052355B (zh) 2008-06-27
IL151829A (en) 2012-03-29
US20020028803A1 (en) 2002-03-07
US7074782B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
DE60132567D1 (de) Carbamat caspase inhibitoren und deren verwendung
ATE277910T1 (de) Urazil verbindungen und deren verwendung
DE60131015D1 (de) Bakterielle gyrase-hemmer und deren verwendung
NO20022656L (no) Caspaseinhibitorer og anvendelse derav
NO20020343L (no) Kaspase-inhibitorer og anvendelse derav
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE420659T1 (de) Criptoblockierende antikörper und deren verwendung
DE60123274D1 (de) Pyrrolcarboxamide und pyrrolcarbothioamide und deren agrochemische verwendungen
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
ATE260033T1 (de) Biozide zusammensetzung und deren verwendung
DE60127860D1 (de) Imidazol- und benzimidazol- caspase inhibitoren und deren verwendung
DE60021507D1 (de) Uracilverbindungen und deren Verwendung
DE60105565D1 (de) Stabiles und wirksames weiches feststoffprodukt
ATE274497T1 (de) Harnstoff- und urethanderivate als integrin inhibitoren
ATE250339T1 (de) Dormanz-brechende zusammenstezung und deren verwendung
DE60013191D1 (de) Tensidzusammensetzung und deren Verwendung
DE60036885D1 (de) Succinimidverbindungen und deren verwendung
DE60100634D1 (de) Optisch-aktive Phosphatverbindung und deren Verwendung
DE29809011U1 (de) Begeh- und befahrbare Fläche
IT1304888B1 (it) Composti monociclici ad azione nk-2 antagonista e formulazioni che licontengono
ATA3042000A (de) Schallabsorptionselement und dessen verwendung
SI1268425T1 (sl) Zaviralci karbamat kaspaze in uporaba le-teh
DE60323849D1 (de) Polybenzazolfaser und deren verwendung
DE69940221D1 (de) Sukralose enthaltende zusammensetzungen sowie deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition